Clinical Scorecard: Management Strategies for Clinical Stage IIA and IIB Seminoma: A Comprehensive Review

At a Glance

Key Highlights

• CS IIA/B seminoma is rare, representing 7% of testicular cancer cases, with excellent survival rates approaching 100%.
• Treatment options include radiotherapy (RT) or chemotherapy (CT), with no definitive high-level evidence favoring one over the other.
• Treatment-related acute and long-term toxicities are critical considerations due to excellent survival outcomes.

Guideline-Based Recommendations

Diagnosis

• Confirm clinical stage IIA/B seminoma by imaging showing retroperitoneal lymph nodes up to 2 cm (IIA) or >2 cm to 5 cm (IIB).
• Exclude non-seminomatous germ cell tumors and other disease stages.

Management

• Offer radiotherapy or chemotherapy following orchiectomy for CS IIA/B seminoma patients.
• Radiotherapy doses ranged from 25.5 to 36 Gy targeting retroperitoneal lymph nodes.
• Chemotherapy regimens include EP (etoposide/cisplatin), BEP (bleomycin/etoposide/cisplatin), and others.

Monitoring & Follow-up

• Monitor for relapse rates, overall survival, and cancer-specific survival over a median follow-up of 3.8 to 10 years.
• Assess acute toxicities such as nausea, diarrhea, neutropenia, and febrile neutropenia.
• Evaluate late toxicities including neuropathy and fertility disorders.

Risks

• Radiotherapy associated with grade 1/2 nausea (92%) and diarrhea (51%), grade 3/4 nausea (8%).
• Chemotherapy associated with grade 3/4 neutropenia (22%) and febrile neutropenia (15%).
• Late toxicities reported in 11% of RT patients and 27% of CT patients.
• Consider risk of treatment-related secondary malignancies.

Patient & Prescribing Data

5049 patients with clinical stage IIA/B seminoma (2840 IIA, 2209 IIB)

Relapse rates were 0%-10.3% for RT in CS IIA and 28.6% in CS IIB; 0% relapse reported for CT in available studies. Overall survival rates at 5 years ranged from 88% to 100% across treatments. Some studies showed statistically significant lower relapse rates and higher survival with CT compared to RT, while others favored RT.

Clinical Best Practices

• Use shared decision-making considering excellent survival and potential acute and long-term toxicities.
• Tailor treatment choice between RT and CT based on patient-specific factors and toxicity profiles.
• Ensure long-term follow-up to monitor for relapse and late treatment-related toxicities.
• Consider fertility preservation strategies prior to treatment initiation.

References

• German Clinical Practice Guideline on Testicular Cancer
• PRISMA Guidelines for Systematic Reviews